Price History

Hover for the daily close. The dotted line marks the period open.

Compare EOCN with… →

EOCN Key Statistics

As of Oct 21, 2026

Trading

Open: $2.97
Previous Close: $3.07
Day's Range: 2.97–3.12
52-Week Range: 2.33–12.32
Volume: 7.03K
Beta: 0.66

Valuation

Market Cap: $3.33M
P/E Ratio: unprofitable
EPS (ttm): −15.21

Financials (FY)

Shares Outstanding: 1.07M

Dividend and dates

Avg Volume: 31.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Recent News

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
Yahoo2026-09-09

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Eocene Ltd. (EOCN) carries a market capitalisation of $3.33M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3.

The most recent close on file for EOCN is $3.12, dated October 21, 2026. That is +$0.05 (+1.60%) against the previous close. The 52-week range on file runs from $2.33 to $12.32. The latest close sits 33.86% above that 52-week low.

Financial Health

Earnings per share on a trailing basis come to −15.21.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.66.

Growth & Income

No dividend is on file for EOCN.

So far in 2026 the total return is −18.78%.

Peer Comparison

Eocene Ltd. (EOCN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Eocene Ltd.	EOCN	$3.33M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Eocene Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Eocene Ltd.

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Visit website →

Eocene Ltd. (EOCN) Stock Analysis